Breast Cancer Therapeutics Market to Witness
Moderate Growth
The breast cancer therapeutics market in the
eight major markets – The US, The UK, France, Germany, Spain, Italy, Japan and
Canada – was worth $9.2 billion in 2013, and is expected to grow at a Compound
Annual Growth Rate (CAGR) of 5.1% to $13.1 billion by 2020. The US had the
largest market in 2013, valued at $5.5 billion, equivalent to a global share of
59%, followed by Japan with $871.5m or 9.4% and Italy with $668.5m or 7.2%.
Canada had the lowest market share and value of the leading eight at 2.9% and
$268.4m, but is expected to witness rapid growth over the forecast period with
a CAGR of 6.7%. This will only be surpassed by Japan, which is expected to
witness growth at a CAGR of 6.9%.
The use of targeted therapies is expected to
increase in the eight major markets, aided by the entry of a biosimilar of
trastuzumab. Drugs in late stages of clinical trials such as palbociclib and
neratinib from Pfizer, and afatinib from Boehringer Ingelheim, are expected to
contribute towards the breast cancer market growth. The market is also expected
to grow due to the increased uptake of Afinitor (everolimus), a novel targeted
therapy from Novartis, despite the high cost of therapy. It will also be driven
by Human Epidermal growth factor Receptor (HER)-2-targeting agents, antibody
drug conjugate Kadcyla (ado-trastuzumab emtansine) and Eisai's Halaven
(eribulin mesylate), a novel chemotherapeutic agent. The total value of the
breast cancer market will increase slightly over the forecast period due to the
increased uptake of branded drugs. This increase will occur despite the launch
of trastuzumab biosimilars, which are likely to actively compete with branded
Herceptin in the breast cancer therapeutics market. Market growth will be the result
of the launch of a number of premium-priced agents, plus a gradual increase in
the use of targeted therapies and a rise in the incidence population in the
eight major markets.
Strong Pipeline to Drive Growth to 2020
The breast cancer pipeline is highly robust
with potential drug candidates across various phases of clinical development.
With over 600 active pipeline molecules, the majority of the investigational
drug candidates are being evaluated for the treatment of breast cancer in
advanced stages, either as first-line or second-line therapies.
The current investigational pipeline
candidates include the new combination therapies, targeted therapies and
promising immunotherapies, as well as chemotherapy drug candidates. In addition
to these active progressing pipeline molecules, the pipeline also includes 390
molecules that are either inactive or discontinued.
As displayed in the following figure, from a
total of 612 active progressing pipeline molecules, 259 (42%) are in the
preclinical stage of development, 100 (16%) are in Phase I, 130 (21%) are in
Phase II and 52 (8%) are in Phase III. A substantial number of active drug
candidates are also in the discovery stage. As shown in panel B, most of the
pipeline drugs are novel, and a few are either generic or products that have
already been marketed for other indications.
Browse this report: http://mrr.cm/ZME
For all Oncology Reports at:
http://www.marketresearchreports.com/oncology
No comments:
Post a Comment
Note: only a member of this blog may post a comment.